Related references
Note: Only part of the references are listed.Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery
W. Cacheux et al.
ANNALS OF ONCOLOGY (2008)
Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials - NSCLC meta-analyses collaborative group
S. Burdett et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
Alex A. Adjei et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
Giorgio Vittorio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Pemetrexed-induced Typhlitis in Non-small Cell Lung Cancer
Marianna Shvartsbeyn et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Bevacizumab Reduces the Growth Rate Constants of Renal Carcinomas: A Novel Algorithm Suggests Early Discontinuation of Bevacizumab Resulted in a Lack of Survival Advantage
Wilfred D. Stein et al.
ONCOLOGIST (2008)
Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer
D. -W. Kim et al.
ANNALS OF ONCOLOGY (2007)
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer
Roy S. Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sequential chemotherapy with combination irinotecan and cisplatin followed by docetaxel for treatment-naive patients with advanced non-small cell lung cancer
Tony S. K. Mok et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Optimal duration of chemotherapy for advanced non-small cell lung cancer: A systematic review and meta-analysis
Yu Soon et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101)
P. Comella et al.
ANNALS OF ONCOLOGY (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer
C. von Plessen et al.
BRITISH JOURNAL OF CANCER (2006)
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial
T Brodowicz et al.
LUNG CANCER (2006)
Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood
RM Bremnes et al.
LUNG CANCER (2006)
A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study
CX Ma et al.
ANNALS OF ONCOLOGY (2006)
Angiogenesis as a therapeutic target
N Ferrara et al.
NATURE (2005)
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
N Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
CG Willett et al.
NATURE MEDICINE (2004)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Pemetrexed in bladder, head and neck, and cervical cancers
L Paz-Ares et al.
SEMINARS IN ONCOLOGY (2002)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
JH Schiller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results
OS Breathnach et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin
IE Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small cell lung cancer
KJ O'Byrne et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
